Sirlander schreef op 29 mei 2020 13:19:
[...]
oké.. ik doe de aanzet en jullie vullen aan en verbeteren ;)
Dear Mr. Gemignani,
Let me start by introducing myself.
I’m a Belgian shareholder of ACPH.
I follow ACPH daily and believe in the company and it’s pipeline a lot. I am active in a forum on beursduivel.be dedicated to ACPH where Belgian and Dutch shareholders share their thoughts.
The launch of Barhemsys is imminent (July we hope) and it surprises us ACPH doesn't garner more attention amongst shareholders..
As we have quite a few biotech companies in Belgium en The Netherlands we can easily compare them.
It strikes us that there is a huge discrepancy between how some of the other biotechs are valued and how ACPH is valued. Other biotechs have a 2024 forward P/S of ten times that of ACPH, even though the growth path is somewhat similar. Of course there are other issues at play but none that can warrant this huge discrepancy..
This makes us wonder if ACPH is doing enough to put itself in the picture.
Maybe this is not the priority of a biotech like ACPH, but if we look at the future prospects of ACPH, we feel they could be better "advertised" for the benefit of both the company and the shareholders.
Other biotechs use Twitter, Linkedin … to give small positive updates. Regular news updates keep the company in the picture and usually benefit the share price.
...